UCB

ATLANTA, May 17, 2013 /PRNewswire/ -- UCB today announced data from a double-blind, placebo-controlled study that found that Neupro(®) (Rotigotine Transdermal System) reduced total nocturnal systolic blood pressure (NSBP) elevations associated with periodic limb movements during sleep (PLMS) and total PLMS in patients with idiopathic moderate-to-severe Restless Legs Syndrome (RLS)/Willis-Ekbom ... read more

ARMONK, N.Y. and BRUSSELS, May 16, 2013 /PRNewswire/ -- regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living ... read more

ATLANTA, April 8, 2013 /PRNewswire/ -- In honor of Parkinson's Awareness Month, former professional football player and coach Forrest Gregg is teaming up with UCB, Inc. to share his personal experiences living with Parkinson's disease (PD) as part of UCB's Parkinson's More Than Motion(TM) campaign. Gregg spent 40 years fighting for ... read more

ATLANTA, March 25, 2013 /PRNewswire/ -- A research collaboration to analyze the clinical factors that impact epilepsy care and outcomes was announced today by the Department of Neurology at Emory University School of Medicine and UCB, a leading biopharmaceutical company. This work is part of an ... read more

ATLANTA, March 19, 2013 /PRNewswire/ -- UCB today announced data from a non-interventional, observational study conducted in Germany that found that when Parkinson's disease (PD) patients were switched from an oral PD medication to Neupro(®) (Rotigotine Transdermal System), they reported improvements in pre-existing gastrointestinal (GI) symptoms. ... read more

ATLANTA, Feb. 20, 2013 /PRNewswire/ -- UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia(®) (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for ... read more

ATLANTA, Jan. 22, 2013 /PRNewswire/ -- Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB and health data-sharing website PatientsLikeMe(®) announce a new study to better understand what factors improve health outcomes for veterans with epilepsy. The ECoE has ... read more

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- UCB, Inc. and the Arthritis Foundation are proud to announce the launch of "Everyday Victories," a program designed to celebrate the individual accomplishments of people succeeding with rheumatoid arthritis (RA). The program provides a platform for the 1.5 million ... read more

ATLANTA, Dec. 5, 2012 /PRNewswire/ -- Health expert and patient advocate Dr. Donnica Moore and global biopharmaceutical company UCB, Inc. are launching Choose Your Move: Take Control of RLS to shed light on the real impact of Restless Legs Syndrome (RLS) and empower those living with the disease to work ... read more

ATLANTA, Dec. 4, 2012 /PRNewswire/ -- Data presented at the 66(th) Annual Meeting of the American Epilepsy Society -- Post hoc, population-based analysis of pivotal trials explored the efficacy of VIMPAT(®) relative to placebo starting from the first week ... read more

ATLANTA, Nov. 30, 2012 /PRNewswire/ -- In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease and inspire those living with the condition to speak out about it. The campaign will ... read more

ATLANTA, Nov. 29, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT(® )(lacosamide) C-V data at the 66(th) Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4. "UCB recognizes the ... read more